Latest Breaking News On - Rudi michelson - Page 6 : comparemela.com

Opthea To Participate at the H C Wainwright BioConnect Conference at NASDAQ

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today

New yorkUnited statesTimothye morrisRudi michelsonHc wainwright bioconnectHershel berryMegan baldwinBlueprint life science groupCompany media enquiriesInvestment in biotechnology companiesOpthea limitedMonsoon communicationsBioconnect conferenceNew york cityMedia enquiries

CLINUVEL Launches CYACÊLLE, Next Generation Solar Care

UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) CLINUVEL.

United statesRudi michelsonDennis wrightMonsoon communicationsScientific officerInvestor relationsMalcolm bullAustralian stock exchange cuv axClinuvel pharmaceuticals limitedSolar careHigh energy visible lightSkin cancer

Global SCENESSE® demand drives increased CLINUVEL revenues,

MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in.

United statesRudi michelsonDarren keamyMonsoon communicationsHalf yearFinancial officerHalf yearly reportInvestor relationsMalcolm bullAustralian stock exchange cuv axClinuvel pharmaceuticals limited

Opthea (OPT) Reports Publication of Phase 2b Trial Results for OPT-302

Opthea (OPT) Reports Publication of Phase 2b Trial Results for OPT-302
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomHershel berryTimothye morrisRudi michelsonMegan baldwinTim jacksonDrug administrationAmerican academy of ophthalmologyConsultant ophthalmic surgeon at king college londonBlueprint life science groupInvestment in biotechnology companiesCompany media enquiriesMonsoon communicationsOpthea limited

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology

Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.